ATE130760T1 - Synergistische wechselwirkung von interleukin-2 und doppelsträngiger rns. - Google Patents

Synergistische wechselwirkung von interleukin-2 und doppelsträngiger rns.

Info

Publication number
ATE130760T1
ATE130760T1 AT88301821T AT88301821T ATE130760T1 AT E130760 T1 ATE130760 T1 AT E130760T1 AT 88301821 T AT88301821 T AT 88301821T AT 88301821 T AT88301821 T AT 88301821T AT E130760 T1 ATE130760 T1 AT E130760T1
Authority
AT
Austria
Prior art keywords
lymphokines
dsrna
human
interleukin
double
Prior art date
Application number
AT88301821T
Other languages
English (en)
Inventor
William A Carter
Original Assignee
Hem Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hem Pharma Corp filed Critical Hem Pharma Corp
Application granted granted Critical
Publication of ATE130760T1 publication Critical patent/ATE130760T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT88301821T 1987-03-03 1988-03-02 Synergistische wechselwirkung von interleukin-2 und doppelsträngiger rns. ATE130760T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2136887A 1987-03-03 1987-03-03

Publications (1)

Publication Number Publication Date
ATE130760T1 true ATE130760T1 (de) 1995-12-15

Family

ID=21803798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88301821T ATE130760T1 (de) 1987-03-03 1988-03-02 Synergistische wechselwirkung von interleukin-2 und doppelsträngiger rns.

Country Status (19)

Country Link
EP (1) EP0281380B1 (de)
JP (1) JPH0713024B2 (de)
KR (1) KR960008009B1 (de)
CN (1) CN1054509C (de)
AT (1) ATE130760T1 (de)
AU (2) AU1256588A (de)
CA (1) CA1336810C (de)
DE (1) DE3854726T2 (de)
DK (1) DK113188A (de)
ES (1) ES2082749T3 (de)
FI (1) FI880961A (de)
IE (1) IE75895B1 (de)
IL (1) IL85603A (de)
NO (1) NO880946L (de)
NZ (1) NZ223720A (de)
PH (1) PH24467A (de)
PT (1) PT86879B (de)
RU (1) RU1836103C (de)
ZA (1) ZA881512B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA881639B (en) * 1987-03-23 1989-02-22 Hem Res Inc Treatment of human viral infection by dsrna combined with viral inhibitors
EP0405315B1 (de) * 1989-06-30 1995-08-23 American Cyanamid Company Verwendung eines phagozytise-aktievierenden Stoffes : LPS oder IL-2 zur Herstellung eines Arzneimittels zur Behandlung von Staphylococcus-aureus-Infektionen bei Kühen
FR2766715B1 (fr) * 1997-08-04 2001-02-16 Scras Produit comprenant au moins de l'arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique simultanee, separee ou etalee dans le temps, dans le traitement d'une maladie virale
AR013269A1 (es) * 1997-08-04 2000-12-13 Scras Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral
FR2768345B1 (fr) * 1997-09-17 2001-05-04 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale, notamment d'une hepatite virale
FR2768344B1 (fr) * 1997-08-26 2001-02-16 Scras Produit comprenant au moins un arn double brin en association avec au moins un agent anti-viral pour une utilisation therapeutique dans le traitement d'une maladie virale
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
KR20010042069A (ko) 1998-03-20 2001-05-25 베니텍 오스트레일리아 리미티드 유전자 발현 조절방법
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AU776150B2 (en) 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
EP1229134A3 (de) 2001-01-31 2004-01-28 Nucleonics, Inc Verwendung von post-transkriptioneller Genabschaltung zur Identifizierung von Nukleinsäuresequenzen die die Funktion einer Zelle beeinflussen
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
EP2116602A1 (de) 2008-05-07 2009-11-11 Institut Gustave Roussy Kombinationsprodukte zur Behandlung von Krebs
EA201290876A1 (ru) 2010-03-05 2013-03-29 Президент Энд Феллоуз Оф Гарвард Колледж Композиции индуцированных дендритных клеток и их использование
WO2016019472A1 (en) 2014-08-08 2016-02-11 Quest Pharmatech Inc. Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer
CA3213217A1 (en) 2021-04-28 2022-11-03 Raphael Darteil Strong potentiation of tlr3 agonists effects using fxr agonists as a combined treatment

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380200D1 (en) * 1982-09-16 1989-08-24 William Alvin Carter Anti-proliferative action of dsnras on tumor cells
CA1326450C (en) * 1985-08-26 1994-01-25 William A. Carter Modulation of aids virus-related events by double stranded rnas (dsrnas)

Also Published As

Publication number Publication date
PT86879B (pt) 1992-05-29
FI880961A0 (fi) 1988-03-02
AU1618992A (en) 1992-08-06
PT86879A (pt) 1988-04-01
DE3854726D1 (de) 1996-01-11
ZA881512B (en) 1988-11-30
EP0281380A3 (en) 1989-09-27
JPS63295514A (ja) 1988-12-01
FI880961A (fi) 1988-09-04
JPH0713024B2 (ja) 1995-02-15
IL85603A0 (en) 1988-08-31
DK113188A (da) 1988-09-04
EP0281380A2 (de) 1988-09-07
IE75895B1 (en) 1997-09-24
IL85603A (en) 1993-05-13
DK113188D0 (da) 1988-03-02
EP0281380B1 (de) 1995-11-29
DE3854726T2 (de) 1996-07-25
CA1336810C (en) 1995-08-29
IE880588L (en) 1988-09-03
NZ223720A (en) 1991-07-26
KR960008009B1 (ko) 1996-06-19
CN1054509C (zh) 2000-07-19
RU1836103C (ru) 1993-08-23
NO880946L (no) 1988-09-05
AU1256588A (en) 1988-09-01
PH24467A (en) 1990-07-18
KR880010776A (ko) 1988-10-24
NO880946D0 (no) 1988-03-03
CN1032296A (zh) 1989-04-12
ES2082749T3 (es) 1996-04-01

Similar Documents

Publication Publication Date Title
ATE130760T1 (de) Synergistische wechselwirkung von interleukin-2 und doppelsträngiger rns.
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
OA08724A (fr) Treatment of human viral infections by dsRNA combined with viral inhibitors.
ATE73347T1 (de) Antivirales immunotherapeutisches mittel und dessen herstellung.
EP0296573A3 (en) Novel nucleosides, their preparation and pharmaceutical novel nucleosides, their preparation and pharmaceutical compositions compositions
EP0306347A3 (en) Diagnosis and treatment of double-stranded rna deficiency states
EP0325018A3 (de) RNase L Inhibitor als Markierung für Virusinfektion
HUT65404A (en) Protection from shock subsequent to injury by double-stranded rnas
ES2061496T3 (es) Tratamiento intralesional del carcinoma de celulas basales con alfa-interferon humano recombinante.
ES2037807T3 (es) Medicamentos que contienen en combinacion interferon y 1-desoxi-piperidinosas, procedimiento para su fabricacion y su aplicacion.
DE69106877D1 (de) Aus blaualgen hergestellte biologisch aktive verbindungen.
EP1013763A4 (de) Interleukin 18 und interleukin 18-convertase des hundes, dafür kodierende dns-moleküle, verfahren für die produktion von interleukin 18 und mittel zur behandlung von erkrankungen des immunsystems beim hund.
DE3462891D1 (en) New pyrimidine derivatives endowed with antiviral activity
ES2072431T3 (es) D-acido aspartico beta-hidroxamato para el tratamiento de infecciones virales y de tumores.
MX9400210A (es) Tratamiento de infecciones virales.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee